Regeneron wins FDA approval for first gene therapy for genetic hearing loss

First-ever gene therapy for hearing loss gets FDA approval: ‘Groundbreaking’

NEWYou can now listen to Fox News articles! A new therapy for genetic hearing loss has just been approved by the Food and Drug Administration (FDA). The treatment, Otarmeni (lunsotogene parvec-cwha), is the first-ever dual adeno-associated virus (AAV) vector-based gene therapy — meaning it uses two harmless viruses to deliver the therapy into cells. In an FDA news release, the agency called the therapy “groundbreaking,” noting its potential to t…

New Gene Therapy Can Restore Hearing in Deaf Kids—And It Comes With an Unexpected Price Tag

A breakthrough FDA-approved treatment is changing how genetic deafness is treated.

First-ever gene therapy for hearing loss gets FDA approval: 'Groundbreaking'

The FDA has approved Otarmeni, the first-ever dual AAV vector-based gene therapy for genetic hearing loss, marking a groundbreaking milestone for patients with OTOF-related deafness.

FDA OKs ‘life-changing’ gene therapy for hearing loss — and it’s free

In a clinical trial of 20 children, 16 saw improvements in their hearing about five months after receiving the "miraculous" gene therapy.

First-Of-Its-Kind Gene Therapy For Inherited Hearing Loss Approved By FDA As Trial Shows Improvement In 80 Percent Of Patients

Some of the children treated with the one-time therapy during the trial have gone on to gain “normal hearing that included whispers.”

The FDA gives the green light to the first gene therapy for deafness

The Food and Drug Administration approved the first gene therapy to restore hearing for people who were born deaf.The decision, while only immediately affecting people born with a very rare form of genetic deafness, is being hailed as a milestone in the quest to treat hearing loss.“It’s the first time in history there’s a new drug for hearing loss,” says Zheng-Yi Chen, an associate scientist at Mass Eye and Ear in Boston who was not involved in …